logo
Plus   Neg
Share
Email

Aeterna: Final Phase 3 Results Show AEZS-130 Safe, Effective In Diagnosing AGHD

Aeterna Zentaris Inc. (AEZS, AEZ.TO) said that final Phase 3 results for its oral ghrelin agonist, AEZS-130, show that the drug is safe and effective in diagnosing adult growth hormone deficiency, or AGHD.

The multicenter open label study was originally designed as a cross-over trial of AEZS-130 vs growth hormone-releasing hormone (GHRH)+L-Arginine (ARG) in AGHD patients and in controls, matched for body mass index, estrogen status, gender and age. After 43 AGHD patients and 10 controls had been tested, GHRH became unavailable. The study was completed by testing 10 more AGHD patients and 38 controls with AEZS-130 alone.

The objective of the clinical trial was to determine the efficacy and safety of AEZS-130 in the diagnosis of AGHD.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In a move likely to escalate the trade dispute between the U.S. and China, President Donald Trump has threatened to impose new tariffs on $200 billion worth of Chinese goods. Trump said in a statement Monday evening he has directed U.S. Trade Representative Robert Lighthizer to identify $200 billion... UBS Group AG Chief Executive Officer Sergio Ermotti said blockchain technology is almost a must for business. In an interview with CNBC, the head of the Swiss banking giant said he believes the technology is definitely an opportunity in the long term. According to him, the technology will help companies free up resources, and blockchain in particular is a great way to increase those efficiencies. In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In...
Follow RTT